首页 > 最新文献

Lancet Hiv最新文献

英文 中文
Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial. 针对南非约翰内斯堡年轻女性的适应性艾滋病暴露前预防干预措施:顺序多分配随机试验。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-13 DOI: 10.1016/S2352-3018(24)00268-6
Jennifer Velloza, Nicole Poovan, Allison Meisner, Nontokozo Ndlovu, Nomhle Ndimande-Khoza, Cole Grabow, Phumzile Zwane, Samukelo Mbele, Mapaseka Molefe, Deborah Donnell, Jared M Baeten, Sybil Hosek, Connie Celum, Sinead Delany-Moretlwe
<p><strong>Background: </strong>Adherence to daily oral pre-exposure prophylaxis (PrEP) is low among African young women, and layered support strategies are needed to improve PrEP adherence in this population. We aimed to evaluate potentially scalable adherence-support strategies for young women aged 18-25 years who initiated PrEP in Johannesburg, South Africa.</p><p><strong>Methods: </strong>We conducted a sequential multiple-assignment randomised trial at Ward 21 of the Wits Reproductive Health and HIV Institute clinical research site, affiliated with University of the Witwatersrand, Johannesburg, South Africa. Participants were eligible if they were assigned female sex at birth, aged 18-25 years, not living with HIV, sexually active, newly initiating PrEP, had regular access to a mobile telephone, and could read. Using sequentially numbered, sealed, opaque envelopes containing group allocation, a staff member assigned enrolled participants (1:1) to receive one of two adherence-support interventions: once per week two-way SMS communication or participation in a WhatsApp peer-support group. Participants assigned to WhatsApp were put into groups with approximately 25 participants, during which they were prompted by staff facilitators to discuss any challenges with PrEP use or other events happening in their lives. The allocation sequence was generated by the data manager using random numbers with variable block sizes between 10 and 14. Only trial investigators were masked to participant intervention assignments; participants, people giving interventions, people assessing outcomes, and people analysing data were not masked to group assignment. All enrolled participants were offered PrEP (ie, co-formulated, once per day oral emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg). The primary outcome was high PrEP adherence at month 9, defined as concentration of tenofovir diphosphate on dried blood sample of 700 fmol per punch or more. At month 3, participants with low PrEP adherence were randomly assigned to a secondary, intensified intervention of issue-focused counselling once per month or drug-level feedback counselling based on PrEP drug concentrations at months 3 and 6. The protocol was registered at ClinicalTrials.gov (NCT04038060) and the trial is complete.</p><p><strong>Findings: </strong>Participants were enrolled and followed up between May 16, 2019, and Jan 25, 2022. From May 16, 2019, to Jan 29, 2021, 401 participants were screened and 360 were enrolled and initiated PrEP. 180 (50%) were randomly assigned to two-way SMS and 180 (50%) were randomly assigned to WhatsApp support groups. At month 9, 34 (20%) of 174 participants in the two-way SMS arm had tenofovir diphosphate 700 fmol per punch or more, compared with 32 (18%) of 174 in the WhatsApp arm (relative risk 1·06, 95% CI 0·69-1·64; p=0·78). At month 9, four (5%) of 76 participants in the drug-level feedback arm had tenofovir diphosphate 700 fmol per punch or more, compared
背景:非洲年轻女性对每日口服暴露前预防药物(PrEP)的依从性较低,因此需要采取分层支持策略来提高该人群对 PrEP 的依从性。我们旨在评估针对南非约翰内斯堡 18-25 岁开始接受 PrEP 的年轻女性可能采取的可扩展的依从性支持策略:我们在南非约翰内斯堡威特沃特斯兰德大学下属的威特斯生殖健康与艾滋病研究所临床研究基地 21 号病房进行了一项连续多次分配随机试验。只要出生时性别为女性、年龄在 18-25 岁之间、未感染 HIV、性生活活跃、刚开始使用 PrEP、经常使用移动电话且识字,就有资格参加试验。工作人员使用按顺序编号、密封的不透明信封(内含小组分配表),将登记的参与者(1:1)分配到两种依从性支持干预措施中的一种:每周一次的双向短信通信或参加 WhatsApp 同伴支持小组。被分配到 WhatsApp 群组的参与者被编入约 25 人的小组,在此期间,工作人员会提示他们讨论使用 PrEP 所面临的任何挑战或生活中发生的其他事件。分配顺序由数据管理员使用随机数生成,组块大小在 10 到 14 之间。只有试验调查人员对参与者的干预分配进行了蒙蔽;参与者、提供干预的人员、评估结果的人员和分析数据的人员均不对分组分配进行蒙蔽。所有参与试验的人员都接受了 PrEP(即共同配制、每天口服一次的恩曲他滨 200 毫克和富马酸替诺福韦二吡呋酯 300 毫克)。主要研究结果是第 9 个月时 PrEP 的高度依从性,即干血样本中的二磷酸替诺福韦浓度达到或超过 700 fmol/punch。在第 3 个月,PrEP 依从性低的参与者被随机分配到次要的强化干预中,即每月一次以问题为重点的咨询或根据第 3 个月和第 6 个月的 PrEP 药物浓度提供药物级别的反馈咨询。该方案已在ClinicalTrials.gov(NCT04038060)上注册,目前试验已经完成:参与者于 2019 年 5 月 16 日至 2022 年 1 月 25 日期间注册并接受随访。从 2019 年 5 月 16 日到 2021 年 1 月 29 日,401 名参与者接受了筛查,360 名参与者注册并开始使用 PrEP。180人(50%)被随机分配到双向短信群组,180人(50%)被随机分配到WhatsApp支持群组。第9个月时,双向短信组的174名参与者中有34人(20%)的二磷酸替诺福韦达到或超过700 fmol/punch,而WhatsApp组的174名参与者中有32人(18%)达到或超过700 fmol/punch(相对风险1-06,95% CI 0-69-1-64;P=0-78)。第9个月时,药物水平反馈组的76名参与者中有4人(5%)的二磷酸替诺福韦达到或超过700 fmol/punch,而每月咨询组的76名参与者中有3人(4%)达到或超过700 fmol/punch(1-33,0-31-5-76;P=0-70)。试验期间共报告了22起严重不良事件,但均被认为与试验无关:在南非约翰内斯堡的年轻女性中,PrEP 在不同干预措施下的依从性并无差异。未来需要研究是否以及如何在资源有限的环境中扩大对年轻女性的 PrEP 支持:美国国立卫生研究院。
{"title":"Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial.","authors":"Jennifer Velloza, Nicole Poovan, Allison Meisner, Nontokozo Ndlovu, Nomhle Ndimande-Khoza, Cole Grabow, Phumzile Zwane, Samukelo Mbele, Mapaseka Molefe, Deborah Donnell, Jared M Baeten, Sybil Hosek, Connie Celum, Sinead Delany-Moretlwe","doi":"10.1016/S2352-3018(24)00268-6","DOIUrl":"https://doi.org/10.1016/S2352-3018(24)00268-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Adherence to daily oral pre-exposure prophylaxis (PrEP) is low among African young women, and layered support strategies are needed to improve PrEP adherence in this population. We aimed to evaluate potentially scalable adherence-support strategies for young women aged 18-25 years who initiated PrEP in Johannesburg, South Africa.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted a sequential multiple-assignment randomised trial at Ward 21 of the Wits Reproductive Health and HIV Institute clinical research site, affiliated with University of the Witwatersrand, Johannesburg, South Africa. Participants were eligible if they were assigned female sex at birth, aged 18-25 years, not living with HIV, sexually active, newly initiating PrEP, had regular access to a mobile telephone, and could read. Using sequentially numbered, sealed, opaque envelopes containing group allocation, a staff member assigned enrolled participants (1:1) to receive one of two adherence-support interventions: once per week two-way SMS communication or participation in a WhatsApp peer-support group. Participants assigned to WhatsApp were put into groups with approximately 25 participants, during which they were prompted by staff facilitators to discuss any challenges with PrEP use or other events happening in their lives. The allocation sequence was generated by the data manager using random numbers with variable block sizes between 10 and 14. Only trial investigators were masked to participant intervention assignments; participants, people giving interventions, people assessing outcomes, and people analysing data were not masked to group assignment. All enrolled participants were offered PrEP (ie, co-formulated, once per day oral emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg). The primary outcome was high PrEP adherence at month 9, defined as concentration of tenofovir diphosphate on dried blood sample of 700 fmol per punch or more. At month 3, participants with low PrEP adherence were randomly assigned to a secondary, intensified intervention of issue-focused counselling once per month or drug-level feedback counselling based on PrEP drug concentrations at months 3 and 6. The protocol was registered at ClinicalTrials.gov (NCT04038060) and the trial is complete.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Participants were enrolled and followed up between May 16, 2019, and Jan 25, 2022. From May 16, 2019, to Jan 29, 2021, 401 participants were screened and 360 were enrolled and initiated PrEP. 180 (50%) were randomly assigned to two-way SMS and 180 (50%) were randomly assigned to WhatsApp support groups. At month 9, 34 (20%) of 174 participants in the two-way SMS arm had tenofovir diphosphate 700 fmol per punch or more, compared with 32 (18%) of 174 in the WhatsApp arm (relative risk 1·06, 95% CI 0·69-1·64; p=0·78). At month 9, four (5%) of 76 participants in the drug-level feedback arm had tenofovir diphosphate 700 fmol per punch or more, compared","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021. 204个国家和地区1990-2021年全球、区域和国家艾滋病毒/艾滋病负担以及到2050年的预测:《2021年全球疾病负担研究》。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1016/S2352-3018(24)00212-1
<p><strong>Background: </strong>As set out in Sustainable Development Goal 3.3, the target date for ending the HIV epidemic as a public health threat is 2030. Therefore, there is a crucial need to evaluate current epidemiological trends and monitor global progress towards HIV incidence and mortality reduction goals. In this analysis, we assess the current burden of HIV in 204 countries and territories and forecast HIV incidence, prevalence, and mortality up to 2050 to allow countries to plan for a sustained response with an increasing number of people living with HIV globally.</p><p><strong>Methods: </strong>We used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 analytical framework to compute age-sex-specific HIV mortality, incidence, and prevalence estimates for 204 countries and territories (1990-2021). We aimed to analyse all available data sources, including data on the provision of HIV programmes reported to UNAIDS, published literature on mortality among people on antiretroviral therapy (ART) identified by a systematic review, household surveys, sentinel surveillance antenatal care clinic data, vital registration data, and country-level case report data. We calibrated a mechanistic simulation of HIV infection and natural history to available data to estimate HIV burden from 1990 to 2021 and generated forecasts to 2050 through projection of all simulation inputs into the future. Historical outcomes (1990-2021) were simulated at the 1000-draw level to support propagation of uncertainty and reporting of uncertainty intervals (UIs). Our approach to forecasting utilised the transmission rate as the basis for projection, along with new rate-of-change projections of ART coverage. Additionally, we introduced two new metrics to our reporting: prevalence of unsuppressed viraemia (PUV), which represents the proportion of the population without a suppressed level of HIV (viral load <1000 copies per mL), and period lifetime probability of HIV acquisition, which quantifies the hypothetical probability of acquiring HIV for a synthetic cohort, a simulated population that is aged from birth to death through the set of age-specific incidence rates of a given time period.</p><p><strong>Findings: </strong>Global new HIV infections decreased by 21·9% (95% UI 13·1-28·8) between 2010 and 2021, from 2·11 million (2·02-2·25) in 2010 to 1·65 million (1·48-1·82) in 2021. HIV-related deaths decreased by 39·7% (33·7-44·5), from 1·19 million (1·07-1·37) in 2010 to 718 000 (669 000-785 000) in 2021. The largest declines in both HIV incidence and mortality were in sub-Saharan Africa and south Asia. However, super-regions including central Europe, eastern Europe, and central Asia, and north Africa and the Middle East experienced increasing HIV incidence and mortality rates. The number of people living with HIV reached 40·0 million (38·0-42·4) in 2021, an increase from 29·5 million (28·1-31·0) in 2010. The lifetime probability of HIV acquisition
背景:正如可持续发展目标3.3所述,终止作为公共卫生威胁的艾滋病毒流行的具体日期是2030年。因此,非常有必要评估当前的流行病学趋势,并监测全球在实现减少艾滋病毒发病率和死亡率目标方面取得的进展。在本分析中,我们评估了204个国家和地区目前的艾滋病毒负担,并预测了到2050年的艾滋病毒发病率、流行率和死亡率,以便各国在全球艾滋病毒感染者人数不断增加的情况下制定持续应对计划。方法:我们使用全球疾病、伤害和风险因素负担研究(GBD) 2021分析框架来计算204个国家和地区(1990-2021)的年龄-性别特异性艾滋病毒死亡率、发病率和流行率估计值。我们的目的是分析所有可用的数据来源,包括向联合国艾滋病规划署报告的艾滋病毒规划的提供数据,通过系统评价确定的抗逆转录病毒治疗(ART)患者死亡率的已发表文献,家庭调查,哨点监测产前保健诊所数据,生命登记数据和国家级病例报告数据。我们根据现有数据校准了HIV感染和自然历史的机制模拟,以估计1990年至2021年的HIV负担,并通过对未来所有模拟输入的预测,生成了到2050年的预测。历史结果(1990-2021)在1000次抽取水平上进行模拟,以支持不确定性的传播和不确定性区间(ui)的报告。我们的预测方法利用传播率作为预测的基础,以及新的抗逆转录病毒治疗覆盖率变化率预测。此外,我们在报告中引入了两个新指标:未抑制病毒血症(PUV)患病率,它代表了未抑制HIV水平的人口比例(病毒载量发现:2010年至2021年间,全球新发HIV感染减少了21.9% (95% UI 13.1 - 28.8),从2010年的211万(20.02 - 2.25)降至2021年的165万(1.48 - 1.82)。与艾滋病毒相关的死亡人数减少了39.7%(33.7 - 44.5),从2010年的1.19万人(1.07 - 1.37人)减少到2021年的71.8万人(66.9 - 78.5万人)。艾滋病毒发病率和死亡率下降幅度最大的是撒哈拉以南非洲和南亚。然而,包括中欧、东欧和中亚以及北非和中东在内的超级区域的艾滋病毒发病率和死亡率不断上升。艾滋病毒感染者人数从2010年的2950万(28.1 - 31.0)增加到2021年的4000万(38.0 - 42.4)。撒哈拉以南非洲超级区域终生感染艾滋病毒的概率仍然最高,从1995年21.8%(20.1 - 24.2)的峰值下降到2021年的8.7%(7.5 - 10.7)。到2021年,七个GBD超级区域中有四个的终生概率低于1%。2021年,撒哈拉以南非洲的PUV最高,为每10万人999·9(857·4-1154·2),但从2003年到2021年,PUV减少了64.5%(58·8- 669·4)。同期,中欧、东欧和中亚地区的PUV增长了11.1%(8.0% ~ 21.2%)。我们的预测显示,全球艾滋病毒发病率和死亡率将持续下降,到2039年,艾滋病毒感染者人数将达到4440万(407 - 498)的峰值,随后逐渐减少。到2025年,我们预计将有143万(1.29 - 1.59)例新的艾滋病毒感染和61.5万(567 -68万)例与艾滋病毒相关的死亡,这表明减少这些数字的2025年中期目标不太可能实现。此外,我们的预测结果表明,很少有国家能够实现2030年将艾滋病毒发病率和与艾滋病毒相关的死亡人数在2010年的基础上减少90%的目标。解释:我们的预测表明,如果继续保持目前的艾滋病毒控制水平,到2030年不太可能实现降低发病率和死亡率的宏伟目标,在未来几十年里,全球将有4000多万人继续需要终身抗逆转录病毒治疗。国际社会将需要显示出持续和实质性的努力,以取得必要的进展,实现并维持终结艾滋病这一公共威胁的目标。资助:比尔和梅林达·盖茨基金会和国家过敏和传染病研究所。
{"title":"Global, regional, and national burden of HIV/AIDS, 1990-2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021.","authors":"","doi":"10.1016/S2352-3018(24)00212-1","DOIUrl":"10.1016/S2352-3018(24)00212-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;As set out in Sustainable Development Goal 3.3, the target date for ending the HIV epidemic as a public health threat is 2030. Therefore, there is a crucial need to evaluate current epidemiological trends and monitor global progress towards HIV incidence and mortality reduction goals. In this analysis, we assess the current burden of HIV in 204 countries and territories and forecast HIV incidence, prevalence, and mortality up to 2050 to allow countries to plan for a sustained response with an increasing number of people living with HIV globally.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We used the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 analytical framework to compute age-sex-specific HIV mortality, incidence, and prevalence estimates for 204 countries and territories (1990-2021). We aimed to analyse all available data sources, including data on the provision of HIV programmes reported to UNAIDS, published literature on mortality among people on antiretroviral therapy (ART) identified by a systematic review, household surveys, sentinel surveillance antenatal care clinic data, vital registration data, and country-level case report data. We calibrated a mechanistic simulation of HIV infection and natural history to available data to estimate HIV burden from 1990 to 2021 and generated forecasts to 2050 through projection of all simulation inputs into the future. Historical outcomes (1990-2021) were simulated at the 1000-draw level to support propagation of uncertainty and reporting of uncertainty intervals (UIs). Our approach to forecasting utilised the transmission rate as the basis for projection, along with new rate-of-change projections of ART coverage. Additionally, we introduced two new metrics to our reporting: prevalence of unsuppressed viraemia (PUV), which represents the proportion of the population without a suppressed level of HIV (viral load &lt;1000 copies per mL), and period lifetime probability of HIV acquisition, which quantifies the hypothetical probability of acquiring HIV for a synthetic cohort, a simulated population that is aged from birth to death through the set of age-specific incidence rates of a given time period.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Global new HIV infections decreased by 21·9% (95% UI 13·1-28·8) between 2010 and 2021, from 2·11 million (2·02-2·25) in 2010 to 1·65 million (1·48-1·82) in 2021. HIV-related deaths decreased by 39·7% (33·7-44·5), from 1·19 million (1·07-1·37) in 2010 to 718 000 (669 000-785 000) in 2021. The largest declines in both HIV incidence and mortality were in sub-Saharan Africa and south Asia. However, super-regions including central Europe, eastern Europe, and central Asia, and north Africa and the Middle East experienced increasing HIV incidence and mortality rates. The number of people living with HIV reached 40·0 million (38·0-42·4) in 2021, an increase from 29·5 million (28·1-31·0) in 2010. The lifetime probability of HIV acquisition","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e807-e822"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612058/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142751643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing HIV prevention and the PrEP gap among migrants. 解决移民中的艾滋病毒预防和 PrEP 差距。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1016/S2352-3018(24)00272-8
Christiana Nöstlinger
{"title":"Addressing HIV prevention and the PrEP gap among migrants.","authors":"Christiana Nöstlinger","doi":"10.1016/S2352-3018(24)00272-8","DOIUrl":"10.1016/S2352-3018(24)00272-8","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e798-e800"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlights of the 5th HIVR4P Conference. 第 5 届 HIVR4P 会议要点。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-06 DOI: 10.1016/S2352-3018(24)00307-2
Adrian Gonzalez-Lopez
{"title":"Highlights of the 5th HIVR4P Conference.","authors":"Adrian Gonzalez-Lopez","doi":"10.1016/S2352-3018(24)00307-2","DOIUrl":"10.1016/S2352-3018(24)00307-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e806"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet HIV 2024; 11: e64-65. Lancet HIV 2024; 11: e64-65 更正。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-03-28 DOI: 10.1016/S2352-3018(24)00091-2
{"title":"Correction to Lancet HIV 2024; 11: e64-65.","authors":"","doi":"10.1016/S2352-3018(24)00091-2","DOIUrl":"10.1016/S2352-3018(24)00091-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e804"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiretrovirals and obesity. 抗逆转录病毒药物与肥胖。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-29 DOI: 10.1016/S2352-3018(24)00298-4
Nikos Pantazis, Kholoud Porter, Caroline A Sabin, Fiona Burns, Giota Touloumi
{"title":"Antiretrovirals and obesity.","authors":"Nikos Pantazis, Kholoud Porter, Caroline A Sabin, Fiona Burns, Giota Touloumi","doi":"10.1016/S2352-3018(24)00298-4","DOIUrl":"10.1016/S2352-3018(24)00298-4","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e802-e803"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extreme weather events and disruptions to HIV services: a systematic review. 极端天气事件与艾滋病服务中断:系统回顾。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-10-09 DOI: 10.1016/S2352-3018(24)00186-3
Collins C Iwuji, Celia McMichael, Euphemia Sibanda, Kingsley S Orievulu, Kelly Austin, Kristie L Ebi

Background: Extreme weather events pose a risk to health and disproportionately affect vulnerable groups, such as people living with HIV. We aimed to investigate the effects of extreme weather events on HIV testing uptake, HIV treatment and care, and HIV transmission.

Methods: For this systematic review, we searched PubMed, Web of Science, and PsycINFO for peer-reviewed studies published between database inception and Aug 31, 2023. Eligible studies were English-language qualitative, quantitative observational (retrospective, prospective, cross-sectional, longitudinal, case-control, and cohort), and mixed-method studies, and randomised controlled trials related to HIV and extreme weather events. We excluded reviews, mathematical models, and case reports. After exporting the search results, two authors independently screened the titles and abstracts of identified articles, reviewing the full text of those that met the inclusion criteria. We used systems thinking to develop a framework linking extreme weather events and HIV and summarised the results using thematic narrative synthesis.

Findings: Of the 6126 studies identified by the search, 27 met the inclusion criteria and were eligible for analysis, of which 19 were quantitative, six were qualitative, and two were mixed-method studies. We identified five main themes linking extreme weather events to HIV: economic and livelihood conditions (12 studies), psychosocial factors (19 studies), infrastructure damage and operational challenges (17 studies), migration and displacement (ten studies), and associated medical conditions and health-care needs (12 studies). We showed how these themes interact in complex ways, resulting in a reduction in uptake of HIV testing, interruption of HIV care and subsequent disease progression, altered risk behaviours, and an increased prevalence of HIV.

Interpretation: Extreme weather events are associated with disruptions to HIV services. Owing to the design of the included studies, we could not establish a causal relationship between extreme weather events and HIV incidence, highlighting a research gap. Appropriate adaptations and mitigation policies that protect the health and wellbeing of people living with HIV during and after extreme weather events are warranted. Such actions will be crucial to achieving the UNAIDS goal of ending HIV as a public health threat by 2030.

Funding: None.

背景:极端天气事件对健康构成风险,对弱势群体(如艾滋病毒感染者)的影响尤为严重。我们旨在调查极端天气事件对艾滋病检测率、艾滋病治疗和护理以及艾滋病传播的影响:在本系统性综述中,我们检索了 PubMed、Web of Science 和 PsycINFO 上从数据库开始到 2023 年 8 月 31 日之间发表的同行评审研究。符合条件的研究包括与 HIV 和极端天气事件相关的英语定性、定量观察(回顾性、前瞻性、横断面、纵向、病例对照和队列)、混合方法研究和随机对照试验。我们排除了综述、数学模型和病例报告。导出搜索结果后,两位作者独立筛选了已确定文章的标题和摘要,并审阅了符合纳入标准的文章全文。我们利用系统思维建立了一个将极端天气事件与艾滋病联系起来的框架,并利用主题叙述综合法对结果进行了总结:在搜索确定的 6126 篇研究中,有 27 篇符合纳入标准,可以进行分析,其中 19 篇为定量研究,6 篇为定性研究,2 篇为混合方法研究。我们确定了将极端天气事件与艾滋病联系起来的五大主题:经济和生计条件(12 项研究)、社会心理因素(19 项研究)、基础设施破坏和运营挑战(17 项研究)、移民和流离失所(10 项研究)以及相关的医疗条件和保健需求(12 项研究)。我们展示了这些主题如何以复杂的方式相互作用,导致艾滋病检测率下降、艾滋病护理中断和随后的疾病进展、风险行为改变以及艾滋病流行率上升:极端天气事件与艾滋病服务中断有关。由于所纳入研究的设计原因,我们无法确定极端天气事件与艾滋病发病率之间的因果关系,这凸显了研究缺口。有必要采取适当的适应和缓解政策,在极端天气事件发生期间和之后保护艾滋病毒感染者的健康和福祉。这些行动对于实现联合国艾滋病规划署到 2030 年消除艾滋病毒对公众健康的威胁这一目标至关重要:资金:无。
{"title":"Extreme weather events and disruptions to HIV services: a systematic review.","authors":"Collins C Iwuji, Celia McMichael, Euphemia Sibanda, Kingsley S Orievulu, Kelly Austin, Kristie L Ebi","doi":"10.1016/S2352-3018(24)00186-3","DOIUrl":"10.1016/S2352-3018(24)00186-3","url":null,"abstract":"<p><strong>Background: </strong>Extreme weather events pose a risk to health and disproportionately affect vulnerable groups, such as people living with HIV. We aimed to investigate the effects of extreme weather events on HIV testing uptake, HIV treatment and care, and HIV transmission.</p><p><strong>Methods: </strong>For this systematic review, we searched PubMed, Web of Science, and PsycINFO for peer-reviewed studies published between database inception and Aug 31, 2023. Eligible studies were English-language qualitative, quantitative observational (retrospective, prospective, cross-sectional, longitudinal, case-control, and cohort), and mixed-method studies, and randomised controlled trials related to HIV and extreme weather events. We excluded reviews, mathematical models, and case reports. After exporting the search results, two authors independently screened the titles and abstracts of identified articles, reviewing the full text of those that met the inclusion criteria. We used systems thinking to develop a framework linking extreme weather events and HIV and summarised the results using thematic narrative synthesis.</p><p><strong>Findings: </strong>Of the 6126 studies identified by the search, 27 met the inclusion criteria and were eligible for analysis, of which 19 were quantitative, six were qualitative, and two were mixed-method studies. We identified five main themes linking extreme weather events to HIV: economic and livelihood conditions (12 studies), psychosocial factors (19 studies), infrastructure damage and operational challenges (17 studies), migration and displacement (ten studies), and associated medical conditions and health-care needs (12 studies). We showed how these themes interact in complex ways, resulting in a reduction in uptake of HIV testing, interruption of HIV care and subsequent disease progression, altered risk behaviours, and an increased prevalence of HIV.</p><p><strong>Interpretation: </strong>Extreme weather events are associated with disruptions to HIV services. Owing to the design of the included studies, we could not establish a causal relationship between extreme weather events and HIV incidence, highlighting a research gap. Appropriate adaptations and mitigation policies that protect the health and wellbeing of people living with HIV during and after extreme weather events are warranted. Such actions will be crucial to achieving the UNAIDS goal of ending HIV as a public health threat by 2030.</p><p><strong>Funding: </strong>None.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e843-e860"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142407069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ending barriers to HIV care for migrant populations. 消除流动人口获得艾滋病毒护理的障碍。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 DOI: 10.1016/S2352-3018(24)00316-3
The Lancet Hiv
{"title":"Ending barriers to HIV care for migrant populations.","authors":"The Lancet Hiv","doi":"10.1016/S2352-3018(24)00316-3","DOIUrl":"https://doi.org/10.1016/S2352-3018(24)00316-3","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"11 12","pages":"e791"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plans to end HIV should address substance use. 终止艾滋病毒的计划应该解决药物使用问题。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 DOI: 10.1016/S2352-3018(24)00297-2
Sandra A Springer
{"title":"Plans to end HIV should address substance use.","authors":"Sandra A Springer","doi":"10.1016/S2352-3018(24)00297-2","DOIUrl":"https://doi.org/10.1016/S2352-3018(24)00297-2","url":null,"abstract":"","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"11 12","pages":"e792-e793"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis. 确保国际移民获得和持续接受艾滋病毒护理的干预措施:证据综述。
IF 12.8 1区 医学 Q1 IMMUNOLOGY Pub Date : 2024-12-01 Epub Date: 2024-11-10 DOI: 10.1016/S2352-3018(24)00175-9
Alena Kamenshchikova, Charlotte M M Peters, Christiana Nöstlinger, Brian Rice, Nathan Ford, Giovanni Ravasi, Fiona Burns, Milosz Parczewski, Christian J P A Hoebe, Nicole Dukers, Farah Seedat, Antons Mozalevskis, Linda-Gail Bekker, Jean Berchmans Tugirimana, Weiming Tang, Gifty Marley, Denis Onyango, Monica C Thormann Peynado, Teymur Noori, Sally Hargreaves

International migrants, especially those belonging to key populations, face a considerable HIV burden. However, continuity of HIV care for this group is often challenged along the migration route. We assess the available evidence on the existing interventions that aim to strengthen community and health systems to ensure the continuity of HIV care for international migrants. We did a systematic search of PubMed for publications from 1989 until 2023 focused on different stages of the HIV care continuum regardless of the geographical region. The literature was reviewed with a thematic approach. Globally, legal regulations can restrict access to HIV care and fuel fear of deportation among undocumented migrants. The intersection of HIV-related and migration-related stigma creates further challenges for uninterrupted access to HIV care along the migration route, with negative clinical and public health consequences. Different potential interventions were identified including: provision of HIV care regardless of migration status; utilisation of mobile health, mobile units, and community-led initiatives to bring HIV care to migrants; and utilisation of participatory and co-creation methods to develop tailored and sustainable HIV-related interventions with migrant communities. Improving access to the continuity of care for migrants requires a shift towards intersectional policies rooted in co-creation approaches to address the underlying multiple and mutually reinforcing inequalities.

国际移民,尤其是属于重点人群的国际移民,面临着相当大的艾滋病毒负担。然而,对这一群体的持续性艾滋病关怀往往在迁徙途中面临挑战。我们对旨在加强社区和医疗系统以确保国际移民艾滋病关怀连续性的现有干预措施的现有证据进行了评估。我们在 PubMed 上系统检索了 1989 年至 2023 年期间的相关文献,这些文献关注的是艾滋病护理连续性的不同阶段,与地理区域无关。我们采用专题方法对文献进行了综述。在全球范围内,法律规定可能会限制无证移民获得艾滋病护理,并加剧他们对被驱逐出境的恐惧。与艾滋病毒相关的污名化和与移民相关的污名化交织在一起,给移民沿途不间断地获得艾滋病毒护理带来了更多挑战,造成了负面的临床和公共卫生后果。会议确定了不同的潜在干预措施,包括:无论移民身份如何,都提供艾滋病毒护理;利用流动医疗、流动医疗队和社区主导的倡议,为移民提供艾滋病毒护理;以及利用参与和共同创造的方法,为移民社区制定量身定制的、可持续的艾滋病毒相关干预措施。要改善移民获得持续护理的机会,就必须转向以共同创造方法为基础的交叉政策,以解决潜在的多重和相互强化的不平等问题。
{"title":"Interventions to ensure access to and continuity of HIV care for international migrants: an evidence synthesis.","authors":"Alena Kamenshchikova, Charlotte M M Peters, Christiana Nöstlinger, Brian Rice, Nathan Ford, Giovanni Ravasi, Fiona Burns, Milosz Parczewski, Christian J P A Hoebe, Nicole Dukers, Farah Seedat, Antons Mozalevskis, Linda-Gail Bekker, Jean Berchmans Tugirimana, Weiming Tang, Gifty Marley, Denis Onyango, Monica C Thormann Peynado, Teymur Noori, Sally Hargreaves","doi":"10.1016/S2352-3018(24)00175-9","DOIUrl":"10.1016/S2352-3018(24)00175-9","url":null,"abstract":"<p><p>International migrants, especially those belonging to key populations, face a considerable HIV burden. However, continuity of HIV care for this group is often challenged along the migration route. We assess the available evidence on the existing interventions that aim to strengthen community and health systems to ensure the continuity of HIV care for international migrants. We did a systematic search of PubMed for publications from 1989 until 2023 focused on different stages of the HIV care continuum regardless of the geographical region. The literature was reviewed with a thematic approach. Globally, legal regulations can restrict access to HIV care and fuel fear of deportation among undocumented migrants. The intersection of HIV-related and migration-related stigma creates further challenges for uninterrupted access to HIV care along the migration route, with negative clinical and public health consequences. Different potential interventions were identified including: provision of HIV care regardless of migration status; utilisation of mobile health, mobile units, and community-led initiatives to bring HIV care to migrants; and utilisation of participatory and co-creation methods to develop tailored and sustainable HIV-related interventions with migrant communities. Improving access to the continuity of care for migrants requires a shift towards intersectional policies rooted in co-creation approaches to address the underlying multiple and mutually reinforcing inequalities.</p>","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":" ","pages":"e873-e884"},"PeriodicalIF":12.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lancet Hiv
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1